Phys.OrgBeam Therapeutics launched to develop Harvard base editing technologyPhys.OrgGenome editing technologies using the CRISPR platform in combination with enzymes like Cas9 and Cpf1 have shown great promise for adjusting genes through insertions or… Continue reading
HealioImmunotherapy options: A future for children with food allergyHealioPediatricians and allergists are facing a growing number of children with food allergy and are weighing the benefits and the risks of new and time-tested forms of immunotherapy t… Continue reading
Does currently available data support the use of oral immunotherapy treatmentsHealioThe general belief is that there is no treatment for food allergies. Food allergies affect more than 15 million Americans and many more worldwide. According to the CDC,… Continue reading
Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy …Bristol Herald Courier (press release) (blog)SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 14, 2018–Allogene Therapeutics, Inc. (Allog… Continue reading
Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy …Bristol Herald Courier (press release) (blog)SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 14, 2018–Allogene Therapeutics, Inc. (Allog… Continue reading
|
Immunicom’s Immunotherapy Product Receives US FDA Breakthrough Device Designation for the Treatment of Cancer
PR Newswire (press release) In contrast to immunotherapy pharmaceuticals and biologicals that introduce foreign compounds and material into a patient’s body, and which are often accompanied by negative side effects, Immunicom’s patented technology is based on a “subtractive” … |
Investing.com |
International Stem Cell Corporation is Valued at $34 Million Market Value by Edison Investment Research
GlobeNewswire (press release) CARLSBAD, Calif., May 14, 2018 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical … International Stem Cell: Moving Forward In Parkinson’s And TBIInvesting.com |
Investing.com |
International Stem Cell Corporation is Valued at $34 Million Market Value by Edison Investment Research
GlobeNewswire (press release) CARLSBAD, Calif., May 14, 2018 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical … International Stem Cell: Moving Forward In Parkinson’s And TBIInvesting.com |